Corticorelin

DRACPC ID  DRACPC0064

Active Ingredients   Corticorelin

Description  Any synthetic therapeutic agent which is chemically identical to or similar to the endogenous human corticotropin-releasing factor (hCRF). Synthesized in the hypothalamus, hCRF stimulates the anterior pituitary gland to secrete adrenocorticotropic hormone (ACTH). In cerebral edema, hCRF acts by impeding the flow of fluid from blood vessels into brain tissue, thereby decreasing edema and stabilizing intracranial pressure. This agent possesses anti-edema properties independent of adrenal gland function.

Synonyms  Recombinant Human Corticotropin Releasing Factor; Therapeutic Corticotropin-Releasing Factor; CFR; Corticoliberin

Type  Biotech

Disease  Brain cancer

Classification

  

Peptide and derivative

Structure Information


Molecular Formula  C208H344N60O63S2

Molecular Weight  4757

Active Sequence  SEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEII

Sequence Length  41

Modification  None

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  Not available

InChI  Not available

InChI_Key Not available

SMILES  Not available

External Codes


PubChem CID  16186200

DrugBank Accession Number  DB05394

NCI Thesaurus Code  C394  

UNII  305OE8862Y   GSRS

CAS  86784-80-7



Drug approval


Drug indication
    Investigated for use/treatment in brain cancer and neurologic disorders.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00088166 A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone Brain Edema; Brain Tumor Phase 3 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.